Question explored with the scientific record
Conversation so far
- 1 treatment for ocular melanoma eye tumour
- 2 what are the chances of cancer spreading to liver after radioactive seedd sewn onto eye
- 3 will radioactive seed treatment save sight?
- 4 basic advice: eye removal versus radioactive seed?
- 5 Do eye hospitals recommend radioactive seed because they want patients to practise this on?
- 6 What ongoing treatment will be needed after radioctive seed treatment?
Answered on this page ↓
What ongoing treatment will be needed after radioctive seed treatment?
The short version: expect a lifetime of eye monitoring, and a high chance of cataract surgery and repeated injections for swelling or fluid under the retina.
Plaque radiation keeps working on the eye for years after the seeds come out. The most common late problem is cataract: in one 384-patient palladium-103 series, 27% developed one, and the rate climbed with lens dose, from about 12% under 4 Gy to 75% at 20 Gy or more [1]. In a 42-patient iodine-125 series for ciliary body melanoma, 55% got cataracts, 24% radiation retinopathy, 15% neovascular glaucoma, and 8% exudative retinal detachment [2]. Iris tumors fared better: 71% of phakic eyes got cataract but no radiation maculopathy or optic neuropathy [3].
Those complications are what drive ongoing treatment. Radiation macular edema is managed with repeated intravitreal injections: four monthly bevacizumab injections improved or stabilized 86% of eyes at 4-6 months [6], and a single dexamethasone implant cut macular thickness by a median 120 µm at one month, with edema recurring at a median of 4 months [7]. Exudative detachment after radiation was treated with dexamethasone implants, with mixed results [5]. Cataract extraction with lens implant was needed in half the cataract cases in one series [3].
| Late problem | Rate in series | Ongoing treatment |
|---|---|---|
| Cataract [1][2][3] | 27% to 71% | Surgery with lens implant |
| Macular edema [6][7] | common | Repeat anti-VEGF or steroid injections |
| Radiation retinopathy [2][4] | 24% to 59% | Injections, laser |
| Neovascular glaucoma [2][4] | 8% to 15% | Pressure-lowering drops, surgery |
What this retrieval cannot see: no record here gives a surveillance schedule, and none tracks lifetime metastatic risk after plaque therapy. Those are the questions to put to your radiation oncologist.
My call: plan for indefinite follow-up and a realistic chance of cataract surgery and injection therapy; the records support that, not a one-and-done procedure. Confidence: moderate on the complications, low on the exact long-term monitoring protocol.
Sources used 7
-
Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy
A single-center prospective-like analysis of 384 consecutive uveal melanoma patients treated with Palladium-103 plaque radiotherapy identifies patient age and lens dose as the strongest predictors of radiation-induced cataract, with anterior tumor location and tumor height also …
DOI: 10.1016/j.ijrobp.2010.02.051 -
Management of ciliary body melanoma with iodine-125 plaque brachytherapy
A retrospective, nonrandomized case series evaluating presentation, management, and outcomes of 42 patients with ciliary body melanoma treated with iodine-125 plaque brachytherapy, showing high tumor control and eye preservation but notable radiation-related ocular morbidity.
DOI: 10.3129/i09-097 -
Lack of Radiation Maculopathy After Palladium-103 Plaque Radiotherapy for Iris Melanoma
103 Pd plaque radiotherapy for iris and iridociliary melanomas yields high local control with no radiation maculopathy or optic neuropathy over a median ~3 years, though cataracts are common and visual acuity largely preserved.
DOI: 10.1016/j.ijrobp.2011.09.033 -
A comparison between 125 Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma
This study compares the treatment efficacy and radiation complications of 125 Iodine brachytherapy and stereotactic radiotherapy in managing juxtapapillary choroidal melanoma, finding comparable efficacy but higher radiation-induced ocular morbidities with stereotactic radiother…
DOI: 10.1136/bjophthalmol-2012-302808 -
Intravitreal Dexamethasone Implant (Ozurdex ® ) for Exudative Retinal Detachment after Proton Beam Therapy for Choroidal Melanoma
This study evaluates the efficacy and safety of intravitreal dexamethasone implant (Ozurdex®) in managing exudative retinal detachment associated with choroidal melanoma treated with proton beam therapy.
DOI: 10.5301/ejo.5000940 -
Monthly Intravitreal Bevacizumab for Macular Edema after Iodine-125 Plaque Radiotherapy of Uveal Melanoma
Monthly intravitreal bevacizumab injections were used to treat macular edema after iodine-125 plaque radiotherapy for uveal melanoma, with 4 monthly injections improving or stabilizing macular thickness and visual acuity in a majority of eyes at 4–6 months.
DOI: 10.5301/ejo.5000352 -
Intravitreal dexamethasone implant in radiation-induced macular oedema
This study evaluates the efficacy and duration of a single intravitreal dexamethasone implant in reducing macular edema and improving visual acuity in patients with radiation maculopathy secondary to eye irradiation for uveal melanoma.
DOI: 10.1136/bjophthalmol-2017-310220